ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Celldex Therapeutics, Inc." (CLDX) Report Updated: Dec 05, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Celldex Therapeutics, Inc." (CLDX)

Rating: Strong Sell Volatility: Aggressive
Total Grade: F Industry: Biotechnology
Competitors: ARIA,EXEL,PIP,ALBO

Stock Analysis

Rating: Monthly View

A
B
C
D
F
December January February March April May June July August September October November

Rating: Weekly View

This Week: F down no change
Last Week: F same downgrade
Two Weeks Ago: D up upgrade
service keys

"Celldex Therapeutics, Inc."© quotemedia

Company Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, as well as in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, as well as in Phase II study for the treatment of metastatic melanoma. It also has various earlier stage drug candidates in clinical development, including varlilumab (CDX-1127), a fully human therapeutic monoclonal antibody for cancer indications; CDX-1401, a targeted immunotherapeutic aimed at antigen presenting cells for cancer indications; and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. The company’s preclinical product candidate includes CDX-014, a fully-human monoclonal antibody-drug conjugate that targets T-cell TIM-1, a molecule, which is upregulated in various cancers comprising renal cell and ovarian carcinomas. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Alteris Therapeutics, Inc.; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc., as well as clinical trial collaboration with Roche Holding, Bristol-Myers Squibb Company, and Oncothyreon Inc. The company is headquartered in Hampton, New Jersey.